日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial

CD19 CAR-T 细胞治疗难治性自身免疫性疾病:CASTLE 篮子试验(1/2 期)

Müller, Fabian; Hagen, Melanie; Wirsching, Andreas; Kharboutli, Soraya; Aigner, Michael; Völkl, Simon; Kretschmann, Sascha; Tascilar, Koray; Taubmann, Jule; Bucci, Laura; Raimondo, Maria Gabriella; Bergmann, Christina; Rothe, Tobias; Corte, Giulia; Tur, Carlo; Muñoz, Luis; Böltz, Sebastian; Schuster, Louis; Hartmann, Fabian; Garantziotis, Panagiotis; Spörl, Silvia; Vasova, Ingrid; Gerbitz, Armin; Spriewald, Bernd; Kiener, Hans; Giannarelli, Diana; Locatelli, Franco; D'Agostino, Maria-Antonietta; Hanssens, Linda; Miltenyi, Stefan; Bozec, Aline; Grieshaber-Bouyer, Ricardo; Mackensen, Andreas; Schett, Georg

Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus

转录组分析揭示系统性红斑狼疮治疗反应的分子机制

Garantziotis, Panagiotis; Moysidou, Georgia Savina; Kapsala, Noemin; Flouda, Sofia; Nikolopoulos, Dionysis; Chavatza, Katerina; Sentis, George; Filia, Anastasia; Malissovas, Nikos; Pieta, Antigone; Banos, Aggelos; Katechis, Spyridon; Fanouriakis, Antonis; Bertsias, George; Boumpas, Dimitrios T

Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage

系统性红斑狼疮损伤风险指数(SLE-DRI):一种基于机器学习的简易工具,用于识别有早期器官损伤风险的患者

Garantziotis, Panagiotis; Nikolopoulos, Dionysis; Katechis, Spyridon; Temiz, Alp; Nöthling, Danae-Mona; Adamichou, Christina; Bergmann, Christina; Sidiropoulos, Prodromos; Schett, Georg; Fanouriakis, Antonis; Boumpas, Dimitrios T; Bertsias, George

Neutrophil Heterogeneity Identifies an Association of LAMP1 With Proliferative Lupus Nephritis

中性粒细胞异质性揭示了LAMP1与增生性狼疮性肾炎的关联

Lennard Ostendorf ,Panagiotis Garantziotis ,Frank Y Huang ,Georg Schett ,Andrea Fava ,Deepak A Rao ,Ricardo Grieshaber-Bouyer

[Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus]

[CD19-CAR T细胞治疗系统性红斑狼疮的长期疗效和安全性随访]

Taubmann, Jule; Böltz, Sebastian; Hagen, Melanie; Wirsching, Andreas; Müller, Fabian; Völkl, Simon; Kharboutli, Soraya; Spörl, Silvia; Garantziotis, Panagiotis; Aigner, Michael; Grieshaber-Bouyer, Ricardo; Mackensen, Andreas; Schett, Georg

Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus

使用达雷木单抗靶向 CD38 治疗难治性系统性红斑狼疮

Lennard Ostendorf, Marie Burns, Pawel Durek, Gitta Anne Heinz, Frederik Heinrich, Panagiotis Garantziotis, Philipp Enghard, Ulrich Richter, Robert Biesen, Udo Schneider, Fabian Knebel, Gerd Burmester, Andreas Radbruch, Henrik E Mei, Mir-Farzin Mashreghi, Falk Hiepe, Tobias Alexander

Epithelial-derived interleukin-23 promotes oral mucosal immunopathology

上皮细胞来源的白细胞介素-23促进口腔黏膜免疫病理学

Tae Sung Kim,Tomoko Ikeuchi,Vasileios Ionas Theofilou,Drake Winslow Williams,Teresa Greenwell-Wild,Armond June,Emmanuel E Adade,Lu Li,Loreto Abusleme,Nicolas Dutzan,Yao Yuan,Laurie Brenchley,Nicolas Bouladoux,Yosuke Sakamachi  ; NIDCD/NIDCR Genomics and Computational Biology Core  ; Robert J Palmer Jr,Ramiro Iglesias-Bartolome,Giorgio Trinchieri,Stavros Garantziotis,Yasmine Belkaid,Alex M Valm,Patricia I Diaz,Steven M Holland,Niki M Moutsopoulos

Epithelial-derived interleukin-23 promotes oral mucosal immunopathology

上皮细胞来源的白细胞介素-23促进口腔黏膜免疫病理学

Tae Sung Kim ,Tomoko Ikeuchi ,Vasileios Ionas Theofilou ,Drake Winslow Williams ,Teresa Greenwell-Wild ,Armond June ,Emmanuel E Adade ,Lu Li ,Loreto Abusleme ,Nicolas Dutzan ,Yao Yuan ,Laurie Brenchley ,Nicolas Bouladoux ,Yosuke Sakamachi ,Ramiro Iglesias-Bartolome ,Giorgio Trinchieri ,Stavros Garantziotis ,Yasmine Belkaid ,Alex M Valm ,Patricia I Diaz ,Steven M Holland ,Niki M Moutsopoulos

Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression

中重度系统性红斑狼疮的实用目标及其对临床治疗和试验设计的影响:持续至少 6 个月的 DORIS 或 LLDAS 评分即可满足治疗要求,而持续至少 24 个月则可确保对无损伤进展具有较高的特异性。

Pitsigavdaki, Sofia; Nikoloudaki, Myrto; Garantziotis, Panagiotis; Silvagni, Ettore; Repa, Argyro; Marangoni, Antonio; Flouri, Irini; Avgoustidis, Nestor; Parperis, Konstantinos; Fanouriakis, Antonis; Govoni, Marcello; Sidiropoulos, Prodromos; Boumpas, Dimitrios T; Bortoluzzi, Alessandra; Bertsias, George

Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events

解开系统性红斑狼疮合并抗磷脂综合征之谜:血液转录组分析揭示静脉和动脉事件中干扰素特征较弱且分子谱存在差异

Nikolopoulos, Dionysis; Loukogiannaki, Catherine; Sentis, George; Garantziotis, Panagiotis; Manolakou, Theodora; Kapsala, Noemin; Nikoloudaki, Myrto; Pieta, Antigone; Flouda, Sofia; Parodis, Ioannis; Bertsias, George; Fanouriakis, Antonis; Filia, Anastasia; Boumpas, Dimitrios T